论文部分内容阅读
目的：观察比较新药普罗布考片与其它两种降血脂药的降脂作用。方法：１９７ 例高脂血症患者随机分组，分别口服藻酸双酯钠片（１００ｍｇ，ｔｉｄ） 、非诺贝特片（１００ｍｇ．ｔｉｄ） 和普罗布考片（２５０ｍｇ．ｂｉｄ）。于第４ 周、第８ 周抽空腹血测定血脂值。结果：服药８ 周后，普罗布考组降血清总胆固醇（ＴＣ）总有效率８４ ．４％ ；藻酸双酯钠组和非诺贝特组分别为７５．５ ％ 和７５．９％ 。服普罗布考期间，仅发现少而轻的不良反应。结论：普罗布考片为安全显效的降血脂药。
Objective: To observe and compare the lipid-lowering effect of probucol tablets and two other lipid-lowering drugs. Methods: A total of 197 patients with hyperlipidemia were randomly divided into two groups: sodium alginate tablets (100mg, tid), fenofibrate tablets (100mg.tid) and probucol tablets (250mg.bid). On the 4th week and the 8th week, fasting blood was measured for blood lipids. Results: After 8 weeks’ administration, the total effective rate of serum total cholesterol (TC) in probucol group was 84%. 4%; alginate diester sodium group and fenofibrate group were 75.5% and 75.9%. During probucol treatment, only a few minor adverse effects were noted. Conclusion: Probucol tablet is a safe and effective hypolipidemic drug.